Introduction {#s1}
============

Major depression occurs in 1% to 3% of older adults and an additional 8% to 16% of elderly patients present with clinically significant depressive symptoms ([@B9]; [@B67]; [@B13]). The prognosis of geriatric depression is poor ([@B13]). Geriatric depression associates with poorer functioning, impairs cognition, increases risk of death from illness, reduces an elderly person's ability to rehabilitate, increases the perception of poor health and the utilization of medical services, and results in significant increase in health care costs ([@B13]). Despite the clinical and societal importance of geriatric depression, it is estimated that only 10% to 20% of patients are diagnosed and adequately treated. Numerous antidepressant drugs have been tested for the treatment of geriatric depression. Among them, selective serotonin reuptake inhibitor (SSRI) drugs, including the potent SSRI fluoxetine, are widely prescribed to treat depression in geriatric patients.

In this overview, the potential vascular side effects of treatment with fluoxetine and other SSRIs in geriatric patients are considered in terms of both the potential proatherogenic effects of the drug and its ability to impair vascular autoregulatory mechanisms ([**Figure 1**](#f1){ref-type="fig"}).

![Proposed scheme depicting potential cardiovascular side effects of SSRI (e.g., fluoxetine) treatment in depressed geriatric patients. The model predicts that due to age-related changes in pharmacokinetics plasma concentrations of SSRIs (shown are fluoxetine and its active metabolite, norfluoxetine) increase. Fluoxetine and other SSRIs may inhibit voltage-dependent Ca^2+^ channels in the vascular smooth muscle cells, attenuating myogenic constriction of resistance arterioles, which may promote orthostatic hypotension and/or exacerbate pressure-induced microvascular damage \[promoting disruption of the blood-brain barrier (BBB) and exacerbating cerebral hemorrhages\]. Cardiac side effects of SSRIs combined with its effect on atherogenesis may promote cardiovascular disease and exacerbate heart failure in geriatric patients.](fgene-10-00898-g001){#f1}

Age-Related Changes in Pharmacokinetics of Fluoxetine and Other SSRIs {#s2}
=====================================================================

With aging, absorption, distribution, metabolism, and excretion of drugs frequently change. Older depressed patients treated with tricyclic antidepressants have been reported to be sensitive to drug toxicity resulting from age‐related pharmacokinetic changes and polypharmacy. Despite a large body of evidence documenting the efficacy and safety of fluoxetine (Prozac) and other SSRIs, there are relatively few published data characterizing age-related changes in pharmacokinetics of fluoxetine and other SSRIs in older patients.

Fluoxetine is well absorbed after oral intake, but it is extensively affected by first-pass metabolism in the liver ([@B2]). Its active metabolite, norfluoxetine, is formed by demethylation of fluoxetine. The cytochrome P450 enzymes CYP2D6, CYP2C19, CYP2C9, CYP3A4, and CYP3A5 have been implicated in the biotransformation of fluoxetine to norfluoxetine ([@B51]; [@B68]). Despite abundant evidence from preclinical studies demonstrating aging-induced reduction in CYP content, activity, and/or inducibility, human studies have yielded mixed results and failed to demonstrate a consistent decline in CYP in older adults ([@B41]). The primary route of elimination of fluoxetine/norfluoxetine is predominantly through oxidative metabolism and conjugation ([@B29]). Fluoxetine/norfluoxetine is mainly excreted in urine. The elimination half-life of fluoxetine and norfluoxetine is approximately 1 to 4 days and 7 to 15 days, respectively ([@B2]). Fluvoxamine has no active metabolites.

The extent of absorption of other SSRIs, including paroxetine, sertraline, and citalopram, from the gastrointestinal tract is generally good ([@B95]). Following absorption paroxetine is almost completely metabolized in the liver ([@B95]). Sertraline also undergoes extensive metabolism ([@B95]). Known pathways for metabolism of citalopram include N-demethylation, deamination, and N-oxidation to less lipophilic compounds to be excreted in urine ([@B95]) (∼12% of a 40-mg dose of citalopram was reported to have been recovered in urine as citalopram, 12% as the main metabolite demethyl-citalopram, 1.5% as amino metabolite, and 4.3% as conjugated propionic acid metabolite ([@B95])). While paroxetine, sertraline, and citalopram do have pharmacologically active metabolites, these are not believed to contribute significantly to the overall clinical effect profile of these SSRIs ([@B95]).

The metabolism of paroxetine, citalopram, and sertraline is impaired in older adults. Steady-state plasma concentrations in the elderly are about twice those measured in younger subjects, and the half-life of paroxetine is twice as long in older adults as in younger individuals ([@B95]). The steady-state pharmacokinetics of citalopram are significantly affected by aging. Steady-state citalopram plasma concentrations after a once-daily 20-mg dose in older individuals were reported to be approximately four times higher than in younger subjects ([@B95]). Plasma concentrations of sertraline were also reported to be higher in older subjects than in young individuals ([@B95]). In contrast with its effect on the pharmacokinetics of other antidepressants, initial studies reported no major age-dependent differences in fluoxetine pharmacokinetics ([@B7]; [@B2]). However, in subsequent studies, it was reported that in older adults following oral treatment with fluoxetine the plasma concentration of its active metabolite norfluoxetine reaches higher levels than in younger individuals ([@B64]; [@B22]). The terminal half-life of norfluoxetine was also reported to be longer in patients older than 75 years ([@B22]). There appears also a sex difference in pharmacokinetics, as elderly women tend to exhibit higher serum levels of norfluoxetine than men ([@B22]). The long half-lives of fluoxetine and norfluoxetine likely promote insidious drug accumulation and manifestation of side effects. Polypharmacy is a common practice in geriatric patients, and potential drug--drug interactions may also affect plasma levels of fluoxetine and norfluoxetine in this patient group.

Vascular Side Effects of Fluoxetine and Other SSRIs: Potential Pathogenic Role of Impaired Myogenic Constriction of Resistance Arteries {#s3}
=======================================================================================================================================

The main mechanism of action of SSRIs, including fluoxetine, depends on their effect to increase the extracellular level of the neurotransmitter serotonin by limiting its reuptake into the presynaptic neurons. This effect results in increased level of serotonin in the synaptic cleft, facilitating its binding to its postsynaptic receptor. However, in the past two decades, preclinical studies demonstrated that fluoxetine, and other SSRIs, also exert significant other cellular effects that are independent of their ability to inhibit serotonin reuptake and involve antagonism of serotonin receptors and inhibition of L-type and T-type voltage-dependent Ca^2+^ channels, as well as other ion channels ([@B55]; [@B56]; [@B90]; [@B17]; [@B58]; [@B91]; [@B81]; [@B88]; [@B39]; [@B28]). Importantly, fluoxetine, as well as other SSRIs, was shown to exert significant vascular effects, including inhibition of pressure-induced myogenic constriction of blood vessels ([@B56]; [@B90]; [@B91]) ([**Figure 1**](#f1){ref-type="fig"}). These vascular effects appear to be mediated by inhibition of L-type voltage-dependent Ca^2+^ channels in the vascular smooth muscle cells ([@B56]; [@B90]; [@B91]). These preclinical observations have important clinical relevance. First, impaired pressure-induced myogenic constriction of peripheral resistance arteries has been implicated in the pathogenesis of orthostatic hypotension. Orthostatic hypotension is very common in geriatric patients and associates with significant morbidity and mortality ([@B32]; [@B45]). Adverse consequences of orthostatic hypotension include falls, fracture, functional decline, and myocardial ischemia. The peripheral vascular effects of SSRIs that promote orthostatic hypotension may be exacerbated by its ability to cause bradycardia as well ([@B55]; [@B57]).

Second, pressure-induced myogenic constriction of cerebral resistance arteries is critical for normal cerebral autoregulation and protection of the vulnerable distal part of the microcirculatory network from penetration of high pressure ([@B87]). Recent studies demonstrate that aging impairs myogenic autoregulatory protection in the brain ([@B82]; [@B83]; [@B84]; [@B75]; [@B87]), potentially exacerbating cerebromicrovascular injury, blood-brain barrier disruption, and neuroinflammation. Importantly, fluoxetine was shown to significantly attenuate pressure-induced myogenic constriction of cerebral arteries ([@B90]). The inhibitory effects of fluoxetine on myogenic constriction of cerebral resistance arteries are likely mediated by its calcium antagonist effects ([@B90]). Indirect evidence suggests that other SSRIs may have similar effects on smooth muscle calcium homeostasis ([@B59]; [@B52]). In addition, fluoxetine was shown to inhibit cytochrome P450--mediated metabolism of arachidonic acid and reduce the formation of 20-HETE by over 70%, at least in part, by down-regulating CYP4A proteins ([@B97]). These are important findings as genetic deficiency in the CYP4A1-mediated formation of 20-HETE was shown to contribute to impaired myogenic response in cerebral arteries and impaired autoregulation of cerebral blood flow ([@B19]; [@B20]). Further, there is also evidence that administration of drugs that inhibit voltage-dependent Ca^2+^ channels or biosynthesis of 20-HETE abolishes myogenic constriction of cerebral arteries *in vitro* ([@B82]; [@B83]; [@B84]; [@B75]) and/or autoregulation of cerebral blood flow *in vivo* ([@B60]). Impairment of myogenic constriction has been linked to increased incidence of intracerebral hemorrhages in aging ([@B83]; [@B84]; [@B86]; [@B79]). In that regard, it is significant that there is epidemiological evidence suggesting that treatment with SSRIs associates with an increased risk of intracerebral hemorrhages ([@B33]). There is also evidence that pathological events traditionally described as "transient ischemic attacks" are, in fact, due to cerebral microhemorrhages. Interestingly, there are clinical observations that initiation of treatment with SSRIs can promote these events ([@B50]). Thus, it should be determined whether in older individuals higher plasma concentrations of SSRIs, including fluoxetine and norfluoxetine, have an exacerbated inhibitory effect on cerebral autoregulatory protection, potentially promoting cerebromicrovascular injury.

Vascular Side Effects of Fluoxetine and Other SSRIs: Potential Pathogenic Role in Atherogenesis {#s4}
===============================================================================================

During the past two decades, increasing evidence has been published, suggesting that treatment of older adults with antidepressants may exert adverse effects on cardiovascular disease outcomes ([@B12]; [@B69]; [@B80]). Previous studies reported that treatment with non-SSRI tricyclic antidepressants results in an increased risk of atherosclerotic vascular disease in older adults ([@B12]). Importantly, epidemiological studies analyzing participants from the ARIC (Atherosclerosis Risk in Communities) study treated with SSRI antidepressants (mean age, 63 ± 10 years, followed for a median of 13.5 years) report a trend for increased risk of cardiovascular disease and stroke (hazard ratios, 1.10 and 1.07, respectively) as compared to patients treated with non-SSRI antidepressants ([@B1]). Consistent with the aforementioned findings, previous studies demonstrate that in depressed monkeys treatment with SSRIs, such as sertraline, also significantly increases atherosclerosis in the carotids and the coronary circulation ([@B70]; [@B71]; [@B72]). Importantly, recent studies demonstrate that in mouse models of atherosclerosis chronic treatment with fluoxetine also promotes atherogenesis by up-regulating vascular inflammation ([@B65]) ([**Figure 1**](#f1){ref-type="fig"}). Interestingly, treatment with a different SSRI, escitalopram, was shown to reduce atherosclerotic changes in high-fat diet--fed rats ([@B93]). The mechanisms underlying these discordant findings are presently unclear. Fluoxetine treatment was demonstrated to induce endothelial activation and promote endothelial cell--leukocyte interaction ([@B36]). Citalopram was also suggested to promote vascular inflammation by increasing leukocyte binding to endothelial cells ([@B65]). In addition, SSRIs may also modulate leukocyte function by interfering with Ca^2+^ signaling mechanisms ([@B28]).

Serotonin is released by activated platelets, contributing to enhanced platelet aggregation and vasoconstriction. Platelets play complex roles in atherogenesis and vessel occlusion upon plaque rupture ([@B26]). Importantly, depressed patients often exhibit a prothrombotic phenotype, which may be modulated by treatment with SSRIs ([@B47]). Treatment with SSRI affects platelet activation ([@B16]; [@B37]; [@B48]) and release of platelet-derived growth factors ([@B38]) that are important regulators of both atherogenic processes and vascular function. Interestingly, treatment with the SSRI paroxetine has been associated with induction of transient ischemic attack ([@B50]), which may be due, at least in part, to the effects of SSRIs on platelet function. Thus, SSRIs may also interfere with atherogenic processes, thrombus formation, and vascular occlusion by modulating platelet function.

Fluoxetine and other SSRIs may also impair function of leukocytes that are critical for organismal defenses against viral infections ([@B27]). Importantly, there are studies extant suggesting that chronic infection with cytomegalovirus (CMV), which exhibits endothelial tropism, promotes atherogenesis. Age-related immunosenescence is thought to contribute to increased prevalence and severity of CMV infection in older adults. Further studies are needed to determine the causal link between SSRI treatment in geriatric patients, immunosenescence, CMV infection, and exacerbation of age-related vascular pathologies.

Antidepressants may also promote weight gain and metabolic disturbances, which may also affect risk of cardiovascular diseases.

Potential Progeronic Effects of Fluoxetine {#s5}
==========================================

Molecular screening studies on the model organism *Caenorhabditis elegans* have identified a range of compounds, including several clinically approved antidepressants, which regulate lifespan and/or cellular resilience to oxidative stressors ([@B61]; [@B62]; [@B96]). Interestingly, several compounds that exert similar antidepressant effects in humans exhibit markedly different effects on cellular aging processes in *C. elegans*. While the structurally related antidepressants mianserin and mirtazapine extend lifespan and increase cellular oxidative stress resistance, fluoxetine exerts marked progeronic effects ([@B66]). Despite recent advances in geroscience ([@B3]; [@B6]; [@B21]; [@B24]; [@B40]; [@B42]; [@B63]; [@B94]) presently its unknown, which pathways involved in regulation of longevity and cellular resilience are modulated by SSRIs. The evolutionarily conserved mTOR (mechanistic target of rapamycin) pathway plays an integral role in the coordination of metabolism, protein synthesis, cell growth, and inflammation and thereby regulates cellular stress resistance, modulates aging processes, and determines mammalian lifespan ([@B34]; [@B44]; [@B15]; [@B23]; [@B43]). Inhibition of mTOR signaling by rapamycin treatment was shown to extend rodent lifespan ([@B34]). Interestingly, there is initial evidence that fluoxetine activates mTOR ([@B46]). Further studies are warranted to determine how fluoxetine alters critical cellular mechanisms of aging in humans and to elucidate whether its action on mTOR may potentially exert progeronic effects. Studies testing the effects of fluoxetine treatment on a wide range of basic cellular mechanisms of aging as well as age-related changes in physiological functions ([@B4]; [@B5]; [@B10]; [@B11]; [@B14]; [@B30]; Liu et al., 2017; [@B77]; [@B78]; [@B79]; [@B92]) would be quite informative in that regard. Another evolutionarily conserved mechanism of aging involves dysregulation of IGF-1 signaling ([@B3]). Several studies have demonstrated that age-related decline in IGF-1 levels contributes significantly to brain and cerebromicrovascular aging ([@B53]; [@B89]; [@B74]; [@B84]; [@B85]; [@B76]; [@B79]). Importantly, there is initial evidence that fluoxetine may affect IGF-1 levels in the central nervous system ([@B18]; [@B31]), but the functional consequences of this effect are not well understood. Increased oxidative stress is a hallmark of aging, including vascular aging. Interestingly, chronic fluoxetine treatment was shown to induce increased oxidative stress in multiple organs ([@B98]) and aging-like phenotypic changes in vascular endothelial function in preclinical models ([@B73]).

Cardiac Side Effects Of SSRIs In Aging {#s6}
======================================

An increasing numbers of older patients with heart failure who develop depressive symptoms are treated with fluoxetine and other SSRIs. The cardiac side effects and toxicity of tricyclic antidepressants, manifested as slowing of intraventricular conduction, have been well documented in medical literature. Although fluoxetine causes significantly fewer cardiac side effects, there are reports in the literature on dysrhythmias, including atrial fibrillation or bradycardia and syncope associated with fluoxetine treatment and overdose (for an overview, see References [@B55]; [@B57]; [@B54]). Preclinical studies confirm that fluoxetine inhibits cardiac Na^+^ and Ca^2+^ channels, which may result in cardiac electrophysiological effects that are similar to those induced by tricyclic antidepressants ([@B58]; [@B49]). Experimental studies also suggest that chronic treatment with fluoxetine and other SSRIs may also compromise autonomic regulation of cardiac function in chronic heart failure ([@B35]). On the basis of the aforementioned observations, the age-related changes in the pharmacokinetics of SSRIs, and potential drug interactions in geriatric patients with cardiac disorders, Electrocardiogram (EKG) control may be suggested during SSRI therapy in the elderly ([**Figure 1**](#f1){ref-type="fig"}).

Perspectives {#s7}
============

The diagnosis and treatment of depression in the elderly can be difficult, particularly in the presence of frailty and comorbidities. Factors to guide treatment choice can include the type of depression, previous response, and concurrent conditions (for strategies for selecting and switching antidepressants to treat geriatric patients, consult References [@B8]; [@B25]). Selective serotonin reuptake inhibitor drugs, including fluoxetine, are the drug of choice for treatment of depression in the elderly: dosage adjustments are not required as frequently with SSRIs as with tricyclic antidepressants or monoamine oxidase inhibitors. Yet, despite the relative safety of SSRIs, these drugs also may have unwanted cardiovascular side effects. With advancing age, changes in drug metabolism and disposition may result in significant increases in the plasma concentrations of SSRIs, which may potentially promote, among others, cardiovascular and cerebrovascular pathologies. The prescriber should be alert to the potential adverse cardiovascular effects of SSRIs when treating depressed geriatric patients and consider the complex interaction between polypharmacy and potential cardiovascular morbidities. Psychological therapies should also be considered for geriatric patients with depression because of the increased vulnerability of these subjects to adverse effects associated with antidepressant treatment.
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